Overview
- Novartis agreed to acquire Pikavation Therapeutics, which holds SNV4818, for $2 billion upfront plus up to $1 billion in milestone payments.
- SNV4818 is an oral, pan‑mutant‑selective PI3Kα inhibitor being tested in a Phase 1/2 trial for breast cancer and other advanced solid tumors.
- The program is designed to spare wild‑type PI3Kα to address tolerability limits seen with non‑selective inhibitors, according to Novartis.
- Preclinical data reported by the company show strong activity against common PIK3CA mutations with clear selectivity over the normal enzyme.
- Novartis positions the asset for potential combinations with CDK inhibitors and endocrine therapies, targeting the roughly 40% of HR+/HER2‑ patients with PIK3CA‑mutant disease, with the deal pending customary approvals in H1 2026.